Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.

Study summary:

Previous investigations have demonstrated that treatment of Helicobacter pylori with antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may potentially benefit patients with Parkinson's disease who have motor fluctuations, specifically excessive "off" time, when their levodopa is not working to control symptoms. We seek to identify the frequency of H. pylori infection in this population using standard lab assays and determine whether eradication with standard triple therapy results in improved clinical response to medication.


Inclusion criteria: - Adults diagnosed with idiopathic Parkinson's disease, Hoehn & Yahr stage 2-4 in the "off" state, with no other concomitant neurologic diseases. - Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy, but with wearing off phenomenon present between levodopa doses (average off time ≥3 hours off time/day). - Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is acceptable. Parkinson's disease treatment may also include any of the following medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B inhibitors, amantadine, anticholinergics. - Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized treatment arms). Exclusion criteria: - Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding. - History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal lesions. - History of previous gastric surgery. - History of previous brain surgery for Parkinson's disease. - Family history of gastric cancer. - Prior treatment for H. pylori+ status. - Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or clarithromycin. - Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole. - Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide). - Inability to tolerate or participate in testing in the morning in an "off" state. - Inability to communicate effectively with study personnel in English. - Pregnancy.



Primary Contact:

Principal Investigator
Jeff M Bronstein, MD, PhD
UCLA Neurology

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.